Xencor stock skyrockets 26% overnight after breakthrough in cancer research

Pallavi Madhiraju- September 9, 2024 0

Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by 26% to $20.39 on Monday following substantial ... Read More

CARsgen Therapeutics completes enrollment in Phase II trial of Satri-cel for advanced gastric cancer

Pallavi Madhiraju- August 20, 2024 0

CARsgen Therapeutics Holdings Limited, a prominent player in the field of CAR T-cell therapies, has announced the successful completion of patient enrollment for its pivotal ... Read More

Exscientia takes full ownership of cdk7 inhibitor in oncology breakthrough

Pallavi Madhiraju- July 20, 2024 0

Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program ... Read More

Roche reports setback in lung cancer study with tiragolumab and tecentriq combination

Pallavi Madhiraju- July 7, 2024 0

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq ... Read More

MediLink Therapeutics, BioNTech expand partnership with new $1.8bn agreement

Pallavi Madhiraju- May 28, 2024 0

MediLink Therapeutics (Suzhou) Co., Ltd., a prominent clinical-stage biotech company, has entered into a significant new strategic collaboration with BioNTech SE, a leader in next-generation ... Read More

Innovent Biologics showcases promising preclinical data at AACR 2024

Pallavi Madhiraju- April 8, 2024 0

In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and ... Read More

FDA grants approval to Yescarta for treatment of certain types of lymphoma

pharmanewsdaily- October 19, 2017 0

In a significant development for lymphoma treatment, Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration (FDA) ... Read More